HIPEC
HIPEC is a pharmaceutical drug with 33 clinical trials. Currently 9 active trials ongoing. Historical success rate of 63.6%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
13
Mid Stage
9
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
58.3%
7 of 12 finished
41.7%
5 ended early
9
trials recruiting
33
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM
Clinical Trials (33)
Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
HIPEC for Peritoneal Carcinomatosis
HIPEC After Radical Cystectomy for High Risk Bladder Cancer
HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy
The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Efficacy of Neoadjuvant Hyperthermic Intraperitoneal Chemotherapy in Advanced High-grade Serous Ovarian Cancer (the NHIPEC Trial)
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis
Immunologic Profile of Peritoneal Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 33